Celgene's β-thalassemia blockbuster luspatercept nears finish line

Celgene's luspatercept is on track for a dual approval after FDA on Tuesday accepted a BLA for the therapy to treat β-thalassemia and myelodysplastic syndrome.

Luspatercept, which is partnered with Acceleron Pharma Inc. (NASDAQ:XLRN), was granted Priority Review for β-thalassemia and assigned a PDUFA date of Dec. 4; the PDUFA date for the MDS indication is April 4, 2020...